In Deutschland sind 10–15% der HIV-Patienten zusätzlich mit Hepatitis C infiziert. Mit der Einführung von Proteasehemmern, die gegen HCV wirksam sind, ist die Behandlung dieser Patienten, zumindest beim HCV-Genotyp 1, effektiver denn je. Was ist bei der Therapie dieser Patienten nun zu berücksichtigen?
This is a preview of subscription content, log in via an institution to check access.
Literatur
Rockstroh JK, Spengler U: HIV and HCV coinfection. Lancet Infect Dis 2004; 4: 437–444
Qurishi N, Kreuzberg C, Lüchters G et al: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 2003; 362: 1708–1713
Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis. 2008; 197: 1558–66
Rockstroh JK. Hot topics in HIV and hepatitis coinfection: noninvasive diagnosis of liver disease, liver transplantation, and new drugs for treatment of hepatitis coinfection. HIV Clin Trials 2009; 10:110–5
Resino S, Asensio C, Bellón JM, et al. Diagnostic accuracy of the APRI, FIB-4, and the Forns index for predicting liver fibrosis in HIV/HCV-coinfected patients: A validation study. J Infect. 2011; 63:402–5
European AIDS Clinical Society. EACS Guidelines. Version 6.0, October 2011. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-6.pdf
Opravil M, Sasadeusz J, Cooper DA et al: Effect of baseline CD4 cell count on the efficacy and safety of peg-interferon-a 2a (40 kd) + ribavirin in patients with HIV-HCV coinfection. J Acquir Immune Def Syndr 2008; 47: 36–49
Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, et al. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother. 2009; 63:1256–63
Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al: peg-interferon-a 2a + ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New Engl J Med 2004; 358: 438–450
Nunez M, Miralles C, Berdun MA et al for the PRESCO study group: Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retrovir 2007, 23: 972–982
Ingiliz P, Rockstroh JK. HIV-HCV coinfection on the eve of HCV protease inhibitor licensing: implications for clinicians. Liver International 2012; in press
Sherman KE, Rockstroh JK, Dieterich DT, et al. Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Coinfected Patients: A 24-Week Treatment Interim Analysis. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases 2011, San Francisco, USA. Abstract LB-8
Sulkowski M, Pol S, Cooper C, et al. Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co.Infected Patients. Infectious Diseases Society of America, 49th Annual Meeting 2011, Boston, USA. Abstract LB-37
Van Heeswijk R, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51st ICAAC Chicago USA 2011, Abstract A1-1738a
Dore GJ, Matthews GV, Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS. 2011;6:508–13
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boesecke, C. Wer profitiert von der Dreifachtherapie?. MMW - Fortschritte der Medizin 154, 42–45 (2012). https://doi.org/10.1007/s15006-012-0626-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-012-0626-x